This video explores the evolving treatment landscape for ROS1-positive non-small cell lung cancer (NSCLC), focusing on targeted therapies, clinical evidence for repotrectinib, management of adverse events, and the pharmacist’s role in improving patient care and adherence.
This video explores the evolving treatment landscape for ROS1-positive non-small cell lung cancer (NSCLC), focusing on targeted therapies, clinical evidence for repotrectinib, management of adverse events, and the pharmacist’s role in improving patient care and adherence.
Pharmacists navigate rapid oncology drug therapy changes, enhancing patient care through education, biomarker insights, and tailored counseling strategies.
Published: September 24th 2025 | Updated:
